Societal CDMO adds six project expansion agreements with existing customers

Societal CDMO announced new project expansion agreements with several existing customers encompassing six new scopes of work across four different current customers. The recently signed work expansion agreements include: increasing the batch size for an ongoing design of experiments study of an approved chemotherapeutic agent: execution of surrogate batch manufacturing and testing for an approved chemotherapeutic agent: analytical method development and validation, along with clinical trial material batch manufacturing of a fixed-dose combination of an approved chemotherapeutic agent: broadening of clinical trial services related to a U.S.-based Phase 2 clinical study of a novel melatonergic antidepressant: dissolution testing on a prototype development batch of a novel multiparticulate-filled formulation of an investigational compound being developed for the treatment of a range of neurodegenerative diseases: dissolution testing on engineering batches of an approved anticancer therapeutic